2026-04-18T07:52:32Zhttps://recercat.cat/oai/request

oai:recercat.cat:20.500.12327/10932025-10-22T11:11:52Zcom_2072_4428com_2072_4427col_2072_487898

Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins Díez, José María Romero, Carolina Serra Gironella, Joan Belló-Perez, Melissa Rodon, Jordi Honrubia, José Manuel Segalés, Joaquim Sola, Isabel Enjuanes, Luis Gajardo, Rodrigo Producció Animal Sanitat Animal 619 Background: Cross-reactivity against human coronaviruses with Flebogamma® DIF and Gamunex®-C, two available intravenous immunoglobulins (IVIG), has been reported. In this study, these IVIG were tested for neutralization activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), SARS-CoV and Middle East respiratory syndrome CoV (MERS-CoV). Materials & methods: Neutralization capacity of lots of IVIG manufactured prior to COVID-19 pandemic was assessed against these viruses in cell culture. Infectivity neutralization was quantified by percent reduction in plaque-forming units and/or cytopathic/cytotoxic methods. Results: All IVIG preparations showed neutralization of SARS-CoV-2 isolates. All IVIG lots produced neutralization of SARS-CoV. No IVIG preparation showed significant neutralizing activity against MERS-CoV. Conclusion: The tested IVIG contain antibodies with significant in vitro cross-neutralization capacity against SARS-CoV-2 and SARS-CoV, but not MERS-CoV. These preparations are currently under evaluation as potential therapies for COVID-19. info:eu-repo/semantics/publishedVersion 2020-09-09 info:eu-repo/semantics/article Díez, José María, Carolina Romero, Júlia Vergara-Alert, Melissa Belló-Perez, Jordi Rodon, José Manuel Honrubia, Joaquim Segalés, Isabel Sola, Luis Enjuanes, and Rodrigo Gajardo. 2020. "Cross-Neutralization Activity Against SARS-Cov-2 Is Present In Currently Available Intravenous Immunoglobulins". Immunotherapy 12 (17): 1247-1255. doi:10.2217/imt-2020-0220. 1750-743X http://hdl.handle.net/20.500.12327/1093 https://doi.org/10.2217/imt-2020-0220 eng Immunotherapy Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess 9 Future Medicine